Change search
ReferencesLink to record
Permanent link

Direct link
EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis
Norfolk and Norwich University Hospital, England; University of East Anglia, England.
University of East Anglia, England; Ipswich Hospital NHS Trust, England.
Leiden University, Netherlands.
University of Barcelona, Spain.
Show others and affiliations
2016 (English)In: Annals of the Rheumatic Diseases, ISSN 0003-4967, E-ISSN 1468-2060, Vol. 75, no 9, 1583-1594 p.Article in journal (Refereed) Published
Abstract [en]

In this article, the 2009 European League Against Rheumatism (EULAR) recommendations for the management of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) have been updated. The 2009 recommendations were on the management of primary small and medium vessel vasculitis. The 2015 update has been developed by an international task force representing EULAR, the European Renal Association and the European Vasculitis Society (EUVAS). The recommendations are based upon evidence from systematic literature reviews, as well as expert opinion where appropriate. The evidence presented was discussed and summarised by the experts in the course of a consensus-finding and voting process. Levels of evidence and grades of recommendations were derived and levels of agreement (strengths of recommendations) determined. In addition to the voting by the task force members, the relevance of the recommendations was assessed by an online voting survey among members of EUVAS. Fifteen recommendations were developed, covering general aspects, such as attaining remission and the need for shared decision making between clinicians and patients. More specific items relate to starting immunosuppressive therapy in combination with glucocorticoids to induce remission, followed by a period of remission maintenance; for remission induction in life-threatening or organ-threatening AAV, cyclophosphamide and rituximab are considered to have similar efficacy; plasma exchange which is recommended, where licensed, in the setting of rapidly progressive renal failure or severe diffuse pulmonary haemorrhage. These recommendations are intended for use by healthcare professionals, doctors in specialist training, medical students, pharmaceutical industries and drug regulatory organisations.

Place, publisher, year, edition, pages
BMJ PUBLISHING GROUP , 2016. Vol. 75, no 9, 1583-1594 p.
Keyword [en]
Systemic vasculitis; Treatment; Cyclophosphamide; Corticosteroids; Disease Activity
National Category
Social and Clinical Pharmacy
URN: urn:nbn:se:liu:diva-132060DOI: 10.1136/annrheumdis-2016-209133ISI: 000383271700007PubMedID: 27338776OAI: diva2:1038451

Funding Agencies|European League Against Rheumatism (EULAR); European Renal Association-European Dialysis and Transplant Association (ERA-EDTA)

Available from: 2016-10-18 Created: 2016-10-17 Last updated: 2016-11-21

Open Access in DiVA

fulltext(443 kB)83 downloads
File information
File name FULLTEXT01.pdfFile size 443 kBChecksum SHA-512
Type fulltextMimetype application/pdf

Other links

Publisher's full textPubMed

Search in DiVA

By author/editor
Segelmark, Mårten
By organisation
Division of Drug ResearchFaculty of Medicine and Health SciencesDepartment of Nephrology
In the same journal
Annals of the Rheumatic Diseases
Social and Clinical Pharmacy

Search outside of DiVA

GoogleGoogle Scholar
Total: 83 downloads
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 71 hits
ReferencesLink to record
Permanent link

Direct link